The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of HER2 and IGF1 germline polymorphisms with outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR) with or without cetuximab (CB): The EPIC experience.
Dongyun Yang
No relevant relationships to disclose
Pierre Oliver Bohanes
No relevant relationships to disclose
Wu Zhang
No relevant relationships to disclose
Christopher Harbison
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ovidiu C. Trifan
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Yan Ning
No relevant relationships to disclose
Leonor Benhaim
No relevant relationships to disclose
Takeru Wakatsuki
No relevant relationships to disclose
Anthony B. El-Khoueiry
No relevant relationships to disclose
Heinz-Josef Lenz
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb